Table 5 Symptoms presented by individuals in the acute phase of COVID-19 according to IgG persistence 90 days after diagnosis
From: Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
Symptoms | 2nd IgG | p* | ||
|---|---|---|---|---|
N | Persistent n = 87 n (%) | Nonpersistent n = 38 n (%) | ||
Fever | 80 | 60 (69.0) | 20 (52.6) | 0.1052 |
Headache | 89 | 63 (72.4) | 26 (68.4) | 0.6718 |
Coryza | 60 | 45 (51.7) | 15 (39.4) | 0.2453 |
Cough | 80 | 61 (70.1) | 18 (47.3) | 0.0257 |
Sore throat | 66 | 47 (54.6) | 19 (50.0) | 0.7011 |
Body pain | 90 | 66 (75.8) | 24 (63.1) | 0.1935 |
Abdominal pain | 32 | 26 (29.8) | 6 (15.8) | 0.1207 |
Diarrhea | 61 | 45 (51.7) | 16 (42.1) | 0.3385 |
Vomiting | 19 | 14 (16.1) | 2 (5.3) | 0.1448 |
Nausea | 37 | 30 (34.4) | 7 (18.2) | 0.0891 |
Anosmia | 90 | 66 (75.9) | 24 (63.2) | 0.3713 |
Ageusia | 86 | 63 (72.4) | 23 (60.5) | 0.8447 |
Shortness of breath | 60 | 46 (52.8) | 14 (36.8) | 0.1208 |
Hair loss | 47 | 36 (41.0) | 11 (28.9) | 0.2303 |